TY - JOUR
T1 - In vitro activity of TNP-2092 against periprosthetic joint infection–associated staphylococci
AU - Fisher, Cody R.
AU - Schmidt-Malan, Suzannah M.
AU - Ma, Zhenkun
AU - Yuan, Ying
AU - He, Shijie
AU - Patel, Robin
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/7
Y1 - 2020/7
N2 - Staphylococci are the most common causes of periprosthetic joint infection (PJI). TNP-2092 is an investigational hybrid drug composed of rifamycin and quinolizinone pharmacophores conjugated via a covalent linker. We determined minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum biofilm bactericidal concentration (MBBC) values of TNP-2092 against 80 PJI-associated Staphylococcus aureus and Staphylococcus epidermidis isolates compared to ciprofloxacin and rifampin alone and in combination, alongside daptomycin and vancomycin. TNP-2092 exhibited the following activity against S. aureus: MIC50/MIC90, ≤0.0075/0.015 μg/mL; MBC50/MBC90, 0.5/4 μg/mL; and MBBC50/MBBC90, 0.5/2 μg/mL, and the following activity against S. epidermidis: MIC50/MIC90, ≤0.0075/0.015 μg/mL; MBC50/MBC90, 0.015/0.125 μg/mL; and MBBC50/MBBC90, 0.06/0.25 μg/mL. TNP-2092 MIC, MBC, and MBBC values were >8 μg/mL for 1 isolate, while MIC values were ≤0.25 μg/mL and MBC and MBBC values were ≤4 μg/mL for all other isolates. Results of this study show that TNP-2092 has promising in vitro activity against PJI-associated staphylococci.
AB - Staphylococci are the most common causes of periprosthetic joint infection (PJI). TNP-2092 is an investigational hybrid drug composed of rifamycin and quinolizinone pharmacophores conjugated via a covalent linker. We determined minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and minimum biofilm bactericidal concentration (MBBC) values of TNP-2092 against 80 PJI-associated Staphylococcus aureus and Staphylococcus epidermidis isolates compared to ciprofloxacin and rifampin alone and in combination, alongside daptomycin and vancomycin. TNP-2092 exhibited the following activity against S. aureus: MIC50/MIC90, ≤0.0075/0.015 μg/mL; MBC50/MBC90, 0.5/4 μg/mL; and MBBC50/MBBC90, 0.5/2 μg/mL, and the following activity against S. epidermidis: MIC50/MIC90, ≤0.0075/0.015 μg/mL; MBC50/MBC90, 0.015/0.125 μg/mL; and MBBC50/MBBC90, 0.06/0.25 μg/mL. TNP-2092 MIC, MBC, and MBBC values were >8 μg/mL for 1 isolate, while MIC values were ≤0.25 μg/mL and MBC and MBBC values were ≤4 μg/mL for all other isolates. Results of this study show that TNP-2092 has promising in vitro activity against PJI-associated staphylococci.
KW - Periprosthetic joint infection
KW - Staphylococcus aureus
KW - Staphylococcus epidermidis
KW - TNP-2092
UR - http://www.scopus.com/inward/record.url?scp=85083715292&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083715292&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2020.115040
DO - 10.1016/j.diagmicrobio.2020.115040
M3 - Article
C2 - 32354459
AN - SCOPUS:85083715292
SN - 0732-8893
VL - 97
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 3
M1 - 115040
ER -